# A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients

> **NCT06355258** · PHASE1 · RECRUITING · sponsor: **Westlake University** · enrollment: 80 (estimated)

## Conditions studied

- COVID 19 Associated Coagulopathy

## Interventions

- **DRUG:** Troxerutin
- **DRUG:** Placebo
- **DRUG:** placebo + low molecular weight heparin
- **DRUG:** troxerutin + low molecular weight heparin

## Key facts

- **NCT ID:** NCT06355258
- **Lead sponsor:** Westlake University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-15
- **Primary completion:** 2024-12
- **Final completion:** 2025-03
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06355258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06355258, "A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06355258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*